Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening
Metrics: PDF 642 views | ?
1 Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
2 Unit of Tumor Genomics, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
3 Unit of Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
4 Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
5 Department of Clinical and Biomedical Sciences Luigi Sacco, University of Milan, Milan, Italy
6 Department of Statistics and Quantitative Methods, Division of Biostatistics, Epidemiology and Public Health, Laboratory of Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy
7 Department of Clinical Sciences, Section of Radiology, University of Parma, Milan, Italy
8 Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
* These authors have contributed equally to this work
Published: October 15, 2019
This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows:
A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4% and an overdiagnosis global rate of 18.5%, reaching 78.9% for indolent cancers in the LDCT arm.
Original article: Oncotarget. 2015; 6:32868–32877. DOI: https://doi.org/10.18632/oncotarget.5210.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.